Agenus Selected for Inclusion in the Russell 3000 Index and Global Index
June 16 2014 - 7:00AM
Business Wire
Agenus, Inc. (NASDAQ:AGEN), an immuno-oncology company
developing a portfolio of checkpoint modulators (CPMs), heat shock
protein vaccines and adjuvants, announced that it has been selected
for inclusion in the broad-market Russell 3000 Index and Russell
Global Index when Russell Investments reconstitutes its
comprehensive set of U.S. and global equity indexes on June 27,
2014, according to a preliminary list of additions on
www.russell.com/indexes.
Annual reconstitution of Russell’s U.S. indexes captures the
4,000 largest U.S. stocks as of the end of May, ranking them by
total market capitalization. Membership in the Russell 3000, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000 Index or small-cap Russell 2000 Index as
well as the appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by
objective, market-capitalization rankings and style attributes.
"We are very pleased to be included in the 2014 reconstitution
of the Russell Indexes,” said Garo H. Armen, Ph.D., chairman and
CEO of Agenus. “We expect our new presence in these indexes will
expose Agenus to a wider range of institutions and investors,
allowing us to broaden our shareholder base."
The Russell 3000 also serves as the U.S. component to the
Russell Global Index, which Russell launched in 2007.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $5.2 trillion in assets
are benchmarked to the Russell Indexes. Russell calculates more
than 700,000 benchmarks daily covering approximately 98 percent of
the investable market globally, more than 80 countries and 10,000
securities. These investment tools originated from Russell’s
multi-manager investment business in the early 1980s when the
company saw the need for a more objective, market-driven set of
benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell 3000 and other Russell
Indexes is available at http://www.russell.com.
About Russell
Russell Investments (Russell) is a global asset manager and one
of only a few firms that offers actively managed multi-asset
portfolios and services that include advice, investments and
implementation. Russell stands with institutional investors,
financial advisors and individuals working with their
advisors—using the firm’s core capabilities that extend across
capital market insights, manager research, portfolio construction,
portfolio implementation and indexes to help each achieve their
desired investment outcomes.
Russell has more than $259 billion in assets under management
(as of 3/31/2014) and works with over 2,500 institutional clients,
independent distribution partners and individual investors
globally. As a consultant to some of the largest pools of capital
in the world, Russell has $2.4 trillion in assets under advisement
(as of 6/30/2013). It has four decades of experience researching
and selecting investment managers and meets annually with more than
2,200 managers around the world. Russell traded more than $1.6
trillion in 2013 through its implementation services business.
Russell also calculates approximately 700,000 benchmarks daily
covering 98% of the investable market globally, including more than
80 countries and more than 10,000 securities. Approximately $5.2
trillion in assets are benchmarked (as of 12/31/2013) to the
Russell Indexes, which have provided investors with 30 years of
smarter beta.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and
adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery
engine Retrocyte Display® is used to generate fully human
therapeutic antibody drug candidates. The Retrocyte Display
platform uses a high-throughput approach incorporating IgG format
human antibody libraries expressed in mammalian B-lineage cells.
Agenus’ heat shock protein vaccines for cancer and infectious
disease are in Phase 2 studies. The company’s QS-21 Stimulon®
adjuvant platform is extensively partnered with GlaxoSmithKline and
Janssen and includes several candidates in Phase 3 trials. For more
information, please visit www.agenusbio.com, or connect with the
company on Facebook, LinkedIn, Twitter and Google+. For more
information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s anticipated inclusion
in Russell Indexes and the impact this could have on our
shareholder base. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our Annual
Report on Form 10-Q filed with the Securities and Exchange
Commission for the year ended March 31, 2014. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this document, and Agenus undertakes no
obligation to update or revise the statements. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. Agenus’ business is subject to substantial
risks and uncertainties, including those identified above. When
evaluating Agenus’ business and securities, investors should give
careful consideration to these risks and uncertainties.
Media and Investors:Jonae R. Barnes, 617-818-2985Vice
President Investor Relations and Corporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024